Austin-based National Instruments is making big investments in autonomous vehicle and safety technology as demand grows for assisted driver innovation.
The company, which recently rebranded as NI, said Tuesday that it has acquired Austin-based monoDrive, a startup that specializes in autonomous vehicle simulations. NI did not disclose financial terms of the deal, but said an undisclosed number of monoDrive employees will NI s staff as part of the acquisition.
In conjunction, NI also said it is entering a strategic collaboration with engineering simulation company Ansys.
NI said the two deals will help accelerate the development of the company’s autonomous vehicle testing technology and help enable vehicle manufacturers and suppliers to speed up the development of self-driving vehicles.
WESTMINSTER Satellite maker Maxar Technologies Inc. (NYSE/TSX: MAXR) saw its stock price shed about 10% in early after-hours trading Monday afternoon as a result of the company’s failure to meet Wall Street expectations for its first quarter earnings.
The company posted a net loss of $84 million, $28 million of which was attributable to the January
“Without this charge, we performed in-line with our expectations for the quarter,” Maxar CEO Dan Jablonsky said in a statement accompanying Maxar’s earnings report.
The net loss was $1.30 per share, significantly higher than Zacks Consensus Estimate of a loss of $0.06.
Sales totalled $392 million for the quarter, up from $381 million in the same period last year but more than $44 million less than Wall Street projections.
Stock Market News for May 3, 2021 Zacks.com 3 hrs ago
Wall Street closed lower on Friday primarily due to profit booking by investors. Moreover, weaker-than-expected earnings results by some big companies also dented investors confidence. All the three major stock indexes ended in red. For the week as a whole, these indexes had mixed performances. However, these indexes performed impressively in April.
Popular Searches
How Did The Benchmarks Perform?
The Dow Jones Industrial Average (DJI) was down 0.5% or 185.51 points to close at 33,874.85. Notably, 21 components of the 30-stock blue-chip index ended in the red while 9 in green. The tech-heavy Nasdaq Composite finished at 13,962.68, tumbling 0.9% or 119.86 points due to weak performance by large-cap technology stocks.
The Zacks Rank Explained: How to Find Strong Buy Consumer Discretionary Stocks Zacks.com 4 hrs ago
It doesn t matter if you re a growth, value, income, or momentum-focused investor building a successful investment portfolio takes skill, research, and a little bit of luck.
Popular Searches
Enter the Zacks Rank.
What is the Zacks Rank?
The Zacks Rank, which is a unique, proprietary stock-rating model, employs earnings estimate revisions, or changes to a company s earnings expectations, that makes building a winning portfolio easier.
There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise.
Agreement is the extent to which all brokerage analysts are revising their earnings estimates in the same direction. The greater the percentage of analysts revising their estimates higher, the better chance the stock will outperform.
AbbVie announced Q1 results on April 30 that chairman and chief executive officer, Richard A. Gonzalez,
described as “ahead of our expectations.” Blockbuster drug, Humira, led the way with global net revenues of $4.867 billion. The company recently took a hit as the suddenly cautious FDA
extended its review of JAK inhibitor, Rinvoq (upadacitinib) for atopic dermatitis, requesting an updated assessment of its benefit-risk profile. This follows the news of a
delay in the approval of Rinvoq for psoriatic arthritis. Rinvoq, which brought in $303 million globally this quarter, is one of the drugs AbbVie is
counting onto allay the loss when patent protection for Humira expires in 2023.